Institut Pasteur

Biovectors Therapeutics S.a.

Boehringer Ingelheim Vetmedica Gmbh

Pierre Perrin

Yves Jacob

Chokri Bahloul

Noël Tordo

Daniel Samain

No&euml;l Tordo

Nathalie Castignolles

The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

Chimeric lyssavirus nucleic acids and polypeptides

The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of aglycoprotein, which has been found to improve the immunogenicity ofepitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode at least site III of a lyssavirus glycoprotein.

Particulate vector and pharmaceutical composition containing it

Growing community of inventors

Montrouge, France

Pierre Perrin